Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2024

Pharma News, 2024

COVID-19 is on the upswing in the US
COVID-19 is on the upswing in the US
COVID-19 hasn't gone away, and data from the Centers for Disease Control and Prevention suggests it's on the upswing around the country.
Researchers develop new chemical method to enhance drug discovery
Researchers develop new chemical method to enhance drug discovery
Moffitt Cancer Center researchers have developed a novel reagent that enhances the precision of drug synthesis. This innovative method, published in Nature Communications, introduces a new sulfur ...
FDA accepts Deciphera’s vimseltinib NDA for priority review
FDA accepts Deciphera’s vimseltinib NDA for priority review
The US Food and Drug Administration (FDA) has accepted for priority review the new drug application (NDA) for Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals’ vimseltinib, a ...
FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer
FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer
AstraZeneca AZN announced that the FDA expanded the label of its blockbuster cancer drug Imfinzi for a fourth indication in lung cancer.
World Health Organization Declares New Mpox Outbreak a Global Public Health Emergency
World Health Organization Declares New Mpox Outbreak a Global Public Health Emergency
The current outbreak has infected more than 14,000 people and spread to 13 different African countries.
Acelyrin deprioritises lead therapy despite Phase III win, fires 33% of staff
Acelyrin deprioritises lead therapy despite Phase III win, fires 33% of staff
As part of pipeline reprioritisation, Acelyrin has dropped izokibep and will instead start Phase III trials for lonigutamab in Q1 2025. Acelyrin has decided to shake up its pipeline; while the company...
FDA grants priority review for Bavarian Nordic’s chikungunya vaccine BLA
FDA grants priority review for Bavarian Nordic’s chikungunya vaccine BLA
The US Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Bavarian Nordic's chikungunya virus vaccine candidate, CHIKV VLP, granting it pri...
Ovid halts preclinical work, IV seizure program in wake of soticlestat's phase 3 stumble
Ovid halts preclinical work, IV seizure program in wake of soticlestat's phase 3 stumble
Ovid Therapeutics already revealed last month that it was trimming back its headcount as the company navigates an unexpected setback for the Takeda-partnered epilepsy med soticlestat. Now, the biotech...
FDA approves Ascendis Pharma’s YORVIPATH for hypoparathyroidism
FDA approves Ascendis Pharma’s YORVIPATH for hypoparathyroidism
Ascendis Pharma has obtained US Food and Drug Administration (FDA) approval for its YORVIPATH (palopegteriparatide) to treat hypoparathyroidism in adults. Hypoparathyroidism is a rare ...
US judge denies initial attempt by Novartis to block generic Entresto launch
US judge denies initial attempt by Novartis to block generic Entresto launch
Novartis’s bid to block the launch of a biosimilar for its best-selling drug Entresto (sacubitril/valsartan) got off to a faltering start, as the drugmaker failed to convince a US court that...
Accelerate Diagnostics completes preclinical trial for antimicrobial test system
Accelerate Diagnostics completes preclinical trial for antimicrobial test system
Accelerate Diagnostics has successfully completed the preclinical trial for its WAVE antimicrobial susceptibility testing system.
FDA Grants Nalmefene Injection Approval for Emergency Treatment of Opioid Overdose
FDA Grants Nalmefene Injection Approval for Emergency Treatment of Opioid Overdose
The FDA announced that they have approved nalmefene auto-injector (Zurnai; Purdue Pharma) for the emergency treatment of known or suspected opioid overdose that is induced by natural or synthe...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand